Nuvalent (NUVL) Net Equity Issued and Repurchased (2020 - 2026)
Nuvalent's (NUVL) quarterly Net Equity Issued and Repurchased came in at $10.1 million in Q1 2026, up 122.55% YoY from $4.6 million in Q1 2025, and down 97.98% on a QoQ basis from $500.6 million in Q4 2025.
Nuvalent (NUVL) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $10.1 million in Q1 2026.
- Quarterly Net Equity Issued and Repurchased rose 122.55% year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $521.3 million (down 6.52% YoY) and the FY2025 annual result came in at $515.7 million, down 9.52% from the prior year.
- Net Equity Issued and Repurchased fell to $10.1 million in Q1 2026, from $500.6 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $540.0 million in Q3 2024 to a low of $619000.0 in Q1 2023.
- A 4-year average of $109.5 million and a median of $5.8 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased soared 38804.9% — and 2025, when it plunged 99.12%.
- Tracing NUVL's Net Equity Issued and Repurchased over 4 years: stood at $334.8 million in 2023, then plunged by 97.38% to $8.8 million in 2024, then soared by 5597.51% to $500.6 million in 2025, then sank by 97.98% to $10.1 million in 2026.
- The last three Net Equity Issued and Repurchased figures came in at $10.1 million (Q1 2026), $500.6 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | 10.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.14 Mn |
| Mar 31, 2026 | 10.14 Mn |
| Dec 31, 2025 | 500.64 Mn |
| Dec 31, 2025 | 500.64 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 5.76 Mn |
| Jun 30, 2025 | 5.76 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | 8.79 Mn |
| Dec 31, 2024 | 8.79 Mn |
| Sep 30, 2024 | 540.00 Mn |
| Sep 30, 2024 | 540.00 Mn |
| Jun 30, 2024 | 4.29 Mn |
| Jun 30, 2024 | 4.29 Mn |
| Mar 31, 2024 | 6.45 Mn |
| Mar 31, 2024 | 6.45 Mn |
| Dec 31, 2023 | 334.81 Mn |
| Dec 31, 2023 | 334.81 Mn |